AAP
FATE icon

Arax Advisory Partners’s Fate Therapeutics FATE Stock Holding History

Arax Advisory Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$918 Buy
+765
New +$931 ﹤0.01% 3319
2025
Q4 		– Sell
-8,570
Closed -$10.8K – 4229
2025
Q3 		$10.8K Buy
+8,570
New +$9.24K ﹤0.01% 2562
2024
Q4 		– Sell
-102
Closed -$357 – 2523
2024
Q3 		$357 Hold
102
– – ﹤0.01% 2450
2024
Q2 		$335 Buy
+102
New +$447 ﹤0.01% 2382

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's FATE Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Fate Therapeutics (FATE) in Q1 2026: 765 shares worth $918. The stake represents ﹤0.01% of the portfolio and ranks #3319 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in FATE as recently as Q3 2025.

Arax Advisory Partners first reported a position in FATE in Q2 2024 and has held it in 4 quarters since. The position peaked at $10.8K in Q3 2025. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Arax Advisory Partners held 765 shares of Fate Therapeutics worth $918 as of Q1 2026.
  • Fate Therapeutics was a new Arax Advisory Partners position in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3319 holding.
  • Arax Advisory Partners first reported a position in Fate Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Arax Advisory Partners's Fate Therapeutics position peaked at $10.8K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.